Last reviewed · How we verify
NMS-03305293
At a glance
| Generic name | NMS-03305293 |
|---|---|
| Sponsor | Nerviano Medical Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer (PHASE1)
- Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer (PHASE1)
- Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (PHASE1, PHASE2)
- Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMS-03305293 CI brief — competitive landscape report
- NMS-03305293 updates RSS · CI watch RSS
- Nerviano Medical Sciences portfolio CI